Good morning, and welcome to the Axsome Therapeutics Fourth Quarter and Full Year 2025 Earnings Conference Call. My name is Kevin, and I'll be your operator for today's call. [Operator Instructions] ...

・Piper said it met with Axsome’s senior management recently, and gained more insights into commercial dynamics surrounding Auvelity in agitation associated with Alzheimer's disease. ・Auvelity is ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Pharma stock Axsome Therapeutics Inc (NASDAQ:AXSM) is soaring to all-time highs, up 19% at $177.13 at last glance, after the U.S. Food & Drug Administration (FDA) granted priority review to AXS-05 -- ...

Axsome Therapeutics AXSM incurred a loss of 71 cents per share in the fourth quarter of 2025, wider than the Zacks Consensus Estimate of a loss of 70 cents. The company had incurred a loss of 96 cents ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Axsome Therapeutics operates as a biopharmaceutical company dedicated to central nervous system (CNS) conditions. Its current commercial lineup includes AUVELITY for depression, SUNOSI for narcolepsy, ...

Axsome Therapeutics AXSM has been witnessing strong uptake for its lead marketed drug, Auvelity (AXS-05), which is approved for treating major depressive disorder. The drug has played an instrumental ...